PUBLIC NOTICE
Wyoming Department of Health
Drug Coverage

Public notice is hereby given that the Wyoming Department of Health intends to submit a State Plan Amendment (SPA) to the United States Department of Health and Human Services Centers for Medicare and Medicaid Services (CMS). Upon CMS approval, the proposed changes will update Attachment 4.19B, Section 12.a. Policy and Methods of Establishing Payment Rate for Each Type of Care Provided in accordance with CMS-2345-FC as indicated in SPA, which will be effective October 1, 2020.

Wyoming Medicaid is updating this State Plan Amendment to implement Medicaid coverage of drugs approved by the Food and Drug Administration (FDA) under an Emergency Use Agreement (EUA) for the indication(s) specified in the applicable EUA.

This update will also describe the reimbursement for drugs used in Medication Assisted Therapy (MAT), which is now a mandatory Medicaid benefit as codified in section 1006(b) of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Calculation of reimbursement of claims for MAT drugs will utilize existing reimbursement methodology for Covered Outpatient Drugs.

The federal fiscal impact associated with this amendment is a $783,725 increase in annual federal spending due to the new coverage of drugs approved under an EUA.

Copies of the Wyoming Medicaid State Plan will be available at the Department of Health, Division of Healthcare Financing. To obtain a copy of the State Plan Amendment, contact:

Cori Cooper,
Division of Healthcare Financing, Medicaid
122 West 25th Street, 4 West
Cheyenne, WY 82002
307-777-6016
cori.cooper@wyo.gov

Dated this twenty-sixth day of February, 2021.

Teri Green, State Medicaid Agent
Wyoming Department of Health
Division of Healthcare Financing